# BCL2L1

## Overview
The BCL2L1 gene encodes the BCL-X protein, a member of the BCL-2 family, which is pivotal in the regulation of apoptosis. This gene produces two main isoforms through alternative splicing: BCL-X_L, which is anti-apoptotic, and BCL-X_S, which is pro-apoptotic. The BCL-X_L protein, characterized by its seven alpha-helical structure, functions primarily to inhibit apoptosis by maintaining mitochondrial integrity and preventing the release of cytochrome c, a critical step in the intrinsic apoptosis pathway. It achieves this by forming heterodimers with pro-apoptotic proteins such as BAX and BAK, thereby blocking their apoptotic activity. BCL-X_L is involved in various cellular processes, including calcium signaling and mitochondrial morphology regulation, and is expressed in tissues with long-lived postmitotic cells, such as the brain. Its role in apoptosis regulation makes it a significant factor in cancer biology, where its overexpression is often associated with treatment resistance (Thomadaki2006BCL2Family; Warren2019BCL-2; Singh2019Regulation).

## Structure
The BCL2L1 gene encodes the BCL-X protein, which has two major isoforms: BCL-X_L and BCL-X_S, arising from alternative splicing. BCL-X_L is anti-apoptotic and consists of 233 amino acids, while BCL-X_S is pro-apoptotic (Thomadaki2006BCL2Family; Warren2019BCL-2). The BCL-X_L protein is composed of seven alpha-helices, with two central hydrophobic helices (α5 and α6) surrounded by five amphipathic helices (Warren2019BCL-2). The BH1, BH2, and BH3 domains are in close proximity, forming a hydrophobic cleft for binding pro-apoptotic proteins (Thomadaki2006BCL2Family; Warren2019BCL-2).

The tertiary structure of BCL-X_L features a hydrophobic groove that facilitates interactions with pro-apoptotic molecules, allowing it to inhibit apoptosis by forming heterodimers with proteins like BAX and BAK (Thomadaki2006BCL2Family; Warren2019BCL-2). The quaternary structure involves dimerization, which is crucial for its function in apoptosis regulation (Lee2019Structural).

Post-translational modifications of BCL2L1 include phosphorylation, which can influence its interactions with other proteins, such as BECN1, affecting its role in autophagy and apoptosis (Lee2019Structural). The BCL-X_L isoform is also involved in calcium signaling regulation and can affect mitochondrial morphology (Warren2019BCL-2).

## Function
The BCL2L1 gene encodes the Bcl-xL protein, a critical member of the BCL-2 family involved in regulating apoptosis, a form of programmed cell death. Bcl-xL functions primarily as an anti-apoptotic protein, inhibiting cell death by maintaining mitochondrial integrity. It prevents the release of cytochrome c from the mitochondria, a key step in the intrinsic apoptosis pathway, thereby blocking the activation of caspases that dismantle the cell (Singh2019Regulation; Varna2011BCL2L1).

Bcl-xL is active in various tissues, particularly those with long-lived postmitotic cells, such as the adult brain, where it helps maintain cellular homeostasis and tissue integrity by regulating mitochondrial membrane potential (Varna2011BCL2L1). It interacts with pro-apoptotic proteins like Bax and Bim, sequestering them to prevent mitochondrial outer membrane permeabilization (MOMP), a critical event in apoptosis (Singh2019Regulation).

In the context of development, Bcl-xL is essential for the survival of differentiating cells, such as pancreatic progenitors derived from human pluripotent stem cells, by modulating apoptosis and supporting cell differentiation and survival (Loo2020BCLxLBCL2L1). Its role in maintaining the balance between cell survival and apoptosis is crucial for normal development and tissue maintenance (Singh2019Regulation).

## Clinical Significance
The BCL2L1 gene, encoding the Bcl-xL protein, plays a significant role in various cancers due to its involvement in apoptosis regulation. In acute myeloblastic leukemia (AML), BCL2L1 is often upregulated, particularly in patients resistant to therapy, contributing to treatment resistance and poor prognosis (Handschuh2021TranscriptLevel). The gene's expression is associated with mutations such as BRCA2 and IDH2, further influencing AML pathogenesis (Handschuh2021TranscriptLevel).

In colorectal cancer, BCL2L1 is frequently amplified, leading to increased Bcl-xL expression, which supports cancer cell survival and therapy resistance. This amplification is observed in about 15% of colorectal cancer cases, making Bcl-xL a potential therapeutic target (Zhang2015Genomic). Inhibiting Bcl-xL in colorectal cancer has shown promise in reducing tumor burden and enhancing apoptosis (Scherr2016BclxL).

Bcl-xL overexpression is also linked to resistance in various other cancers, including breast, ovarian, and prostate cancers, as well as glioblastoma and melanoma. This overexpression contributes to chemotherapy and radiotherapy resistance, complicating treatment strategies (Dou2021Aberrant). The balance between Bcl-xL and its pro-apoptotic isoform Bcl-xS is crucial, as aberrant splicing favoring Bcl-xL can drive cancer progression (Dou2021Aberrant).

## Interactions
BCL2L1, also known as Bcl-xL, is a member of the Bcl-2 family of proteins that plays a crucial role in regulating apoptosis. Bcl-xL interacts with a variety of proteins, primarily through its ability to bind to BH3 domains. It forms a complex with the BH3 domain of Beclin-1, a protein involved in autophagy, suggesting a link between autophagy and apoptosis. This interaction is characterized by the binding of the amphipathic BH3 helix of Beclin-1 to a hydrophobic groove on Bcl-xL, forming a stable complex (Feng2007Molecular; Oberstein2007Crystal).

The interaction between Bcl-xL and Beclin-1 involves both hydrophobic and electrostatic interactions, with specific residues in the BH3 domain of Beclin-1 playing critical roles. Mutations in these residues can significantly affect binding affinity, highlighting the specificity of this interaction (Feng2007Molecular; Oberstein2007Crystal). Bcl-xL also interacts with other BH3-only proteins such as Bad, Bim, and Bak, demonstrating its versatile target-binding capabilities. These interactions involve conformational changes in Bcl-xL, particularly in the α3 helix and the α2/α3 loop, which allow it to accommodate diverse BH3 domains (Feng2007Molecular). These interactions are crucial for the regulation of apoptosis and have implications for tumor suppression and cell death processes.


## References


[1. (Zhang2015Genomic) Haichao Zhang, John Xue, Paul Hessler, Stephen K. Tahir, Jun Chen, Sha Jin, Andrew J. Souers, Joel D. Leverson, and Lloyd T. Lam. Genomic analysis and selective small molecule inhibition identifies bcl-xl as a critical survival factor in a subset of colorectal cancer. Molecular Cancer, July 2015. URL: http://dx.doi.org/10.1186/s12943-015-0397-y, doi:10.1186/s12943-015-0397-y. This article has 41 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s12943-015-0397-y)

[2. (Lee2019Structural) Erinna F. Lee, Nicholas A. Smith, Tatiana P. Soares da Costa, Nastaran Meftahi, Shenggen Yao, Tiffany J. Harris, Sharon Tran, Anne Pettikiriarachchi, Matthew A. Perugini, David W. Keizer, Marco Evangelista, Brian J. Smith, and W. Douglas Fairlie. Structural insights into bcl2 pro-survival protein interactions with the key autophagy regulator becn1 following phosphorylation by stk4/mst1. Autophagy, 15(5):785–795, January 2019. URL: http://dx.doi.org/10.1080/15548627.2018.1564557, doi:10.1080/15548627.2018.1564557. This article has 32 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1080/15548627.2018.1564557)

[3. (Thomadaki2006BCL2Family) Hellinida Thomadaki and Andreas Scorilas. Bcl2family of apoptosis-related genes: functions and clinical implications in cancer. Critical Reviews in Clinical Laboratory Sciences, 43(1):1–67, January 2006. URL: http://dx.doi.org/10.1080/10408360500295626, doi:10.1080/10408360500295626. This article has 180 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/10408360500295626)

[4. (Dou2021Aberrant) Zhihui Dou, Dapeng Zhao, Xiaohua Chen, Caipeng Xu, Xiaodong Jin, Xuetian Zhang, Yupei Wang, Xiaodong Xie, Qiang Li, Cuixia Di, and Hong Zhang. Aberrant bcl-x splicing in cancer: from molecular mechanism to therapeutic modulation. Journal of Experimental &amp; Clinical Cancer Research, June 2021. URL: http://dx.doi.org/10.1186/s13046-021-02001-w, doi:10.1186/s13046-021-02001-w. This article has 23 citations.](https://doi.org/10.1186/s13046-021-02001-w)

[5. (Warren2019BCL-2) Chloe F. A. Warren, Michelle W. Wong-Brown, and Nikola A. Bowden. Bcl-2 family isoforms in apoptosis and cancer. Cell Death &amp; Disease, February 2019. URL: http://dx.doi.org/10.1038/s41419-019-1407-6, doi:10.1038/s41419-019-1407-6. This article has 402 citations.](https://doi.org/10.1038/s41419-019-1407-6)

[6. (Singh2019Regulation) Rumani Singh, Anthony Letai, and Kristopher Sarosiek. Regulation of apoptosis in health and disease: the balancing act of bcl-2 family proteins. Nature Reviews Molecular Cell Biology, 20(3):175–193, January 2019. URL: http://dx.doi.org/10.1038/s41580-018-0089-8, doi:10.1038/s41580-018-0089-8. This article has 1291 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41580-018-0089-8)

[7. (Varna2011BCL2L1) M Varna, P Ratajczak, P Bertheau, and A Janin. Bcl2l1 (bcl2-like 1). Atlas of Genetics and Cytogenetics in Oncology and Haematology, November 2011. URL: http://dx.doi.org/10.4267/2042/44848, doi:10.4267/2042/44848. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.4267/2042/44848)

[8. (Loo2020BCLxLBCL2L1) Larry Sai Weng Loo, Andreas Alvin Purnomo Soetedjo, Hwee Hui Lau, Natasha Hui Jin Ng, Soumita Ghosh, Linh Nguyen, Vidhya Gomathi Krishnan, Hyungwon Choi, Xavier Roca, Shawn Hoon, and Adrian Kee Keong Teo. Bcl-xl/bcl2l1 is a critical anti-apoptotic protein that promotes the survival of differentiating pancreatic cells from human pluripotent stem cells. Cell Death &amp; Disease, May 2020. URL: http://dx.doi.org/10.1038/s41419-020-2589-7, doi:10.1038/s41419-020-2589-7. This article has 32 citations.](https://doi.org/10.1038/s41419-020-2589-7)

[9. (Scherr2016BclxL) Anna-Lena Scherr, Georg Gdynia, Mariam Salou, Praveen Radhakrishnan, Katarina Duglova, Anette Heller, Sophia Keim, Nicole Kautz, Adam Jassowicz, Christin Elssner, You-Wen He, Dirk Jaeger, Mathias Heikenwalder, Martin Schneider, Achim Weber, Wilfried Roth, Henning Schulze-Bergkamen, and Bruno Christian Koehler. Bcl-xl is an oncogenic driver in colorectal cancer. Cell Death &amp; Disease, 7(8):e2342–e2342, August 2016. URL: http://dx.doi.org/10.1038/cddis.2016.233, doi:10.1038/cddis.2016.233. This article has 79 citations.](https://doi.org/10.1038/cddis.2016.233)

[10. (Oberstein2007Crystal) Adam Oberstein, Philip D. Jeffrey, and Yigong Shi. Crystal structure of the bcl-xl-beclin 1 peptide complex. Journal of Biological Chemistry, 282(17):13123–13132, April 2007. URL: http://dx.doi.org/10.1074/jbc.m700492200, doi:10.1074/jbc.m700492200. This article has 461 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m700492200)

[11. (Handschuh2021TranscriptLevel) Luiza Handschuh, Pawel Wojciechowski, Maciej Kazmierczak, and Krzysztof Lewandowski. Transcript-level dysregulation of bcl2 family genes in acute myeloblastic leukemia. Cancers, 13(13):3175, June 2021. URL: http://dx.doi.org/10.3390/cancers13133175, doi:10.3390/cancers13133175. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cancers13133175)

[12. (Feng2007Molecular) Wei Feng, Siyi Huang, Hao Wu, and Mingjie Zhang. Molecular basis of bcl-xl’s target recognition versatility revealed by the structure of bcl-xl in complex with the bh3 domain of beclin-1. Journal of Molecular Biology, 372(1):223–235, September 2007. URL: http://dx.doi.org/10.1016/j.jmb.2007.06.069, doi:10.1016/j.jmb.2007.06.069. This article has 142 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.jmb.2007.06.069)